

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, terms used in this announcement shall have the same meanings as those defined in the prospectus dated May 31, 2017 (the “**Prospectus**”) issued by WuXi Biologics (Cayman) Inc. (the “**Company**”).

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong) (the “**Stabilizing Rules**”).

This announcement is for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for Shares or any securities. Potential investors should read the Prospectus for detailed information about the Global Offering illustrated below before deciding whether or not to invest in the Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or any state securities laws of the United States and may be offered and sold (a) in the United States only to persons who are both “**Qualified Institutional Buyers**” and “**Qualified Purchasers**” in reliance on Rule 144A or another exemption from, or in a transaction not subject to, registration under the U.S. Securities Act and (b) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act. The Company has not intended and does not intend to make any public offer of securities in the United States. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and that will contain detailed information about the Company and management, as well as financial statements. No registration has been or will be made under the United States Investment Company Act of 1940.

WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company announces that the stabilization period in connection with the Global Offering ended on July 5, 2017.

The stabilizing actions undertaken by Morgan Stanley Asia Limited, its affiliates or any person acting for it, being the Stabilizing Manager, during the stabilization period involved:

- (i) over-allocations of an aggregate of 28,947,000 Shares in the International Offering, representing approximately 15% of the Offer Shares initially available under the Global Offering before the exercise of the Over-allotment Option;
- (ii) borrowing of an aggregate of 28,947,000 Shares by Morgan Stanley & Co. International plc from Biologics Holdings to cover over-allocations in the International Offering; and
- (iii) the full exercise of the Over-allotment Option by the Joint Global Coordinators (on behalf of the International Underwriters) on June 14, 2017 in respect of 28,947,000 additional new Shares issued and allotted by the Company to facilitate the return to Biologics Holdings of the 28,947,000 borrowed Shares.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company announces, pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), that the stabilization period in connection with the Global Offering ended on July 5, 2017.

The stabilizing actions undertaken by Morgan Stanley Asia Limited, its affiliates or any person acting for it, being the Stabilizing Manager, during the stabilization period involved:

- (i) over-allocations of an aggregate of 28,947,000 Shares in the International Offering, representing approximately 15% of the Offer Shares initially available under the Global Offering before the exercise of the Over-allotment Option;
- (ii) borrowing of an aggregate of 28,947,000 Shares by Morgan Stanley & Co. International plc from Biologics Holdings to cover over-allocations in the International Offering; and
- (iii) the full exercise of the Over-allotment Option by the Joint Global Coordinators (on behalf of the International Underwriters) on June 14, 2017 in respect of 28,947,000 additional new Shares issued and allotted by the Company to facilitate the return to Biologics Holdings of the 28,947,000 borrowed Shares.

For further details of the full exercise of the Over-allotment Option, please refer to the announcement of the Company dated June 14, 2017.

By order of the Board of Directors
Dr. Ge Li
Chairman

Hong Kong, July 5, 2017

As of the date of this announcement, the Board of Directors comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Edward Hu, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Wo Felix Fong as independent non-executive Directors.

** For identification purpose only*